术前诱导化疗对晚期可手术切除的舌体鳞状细胞癌预后生存的长期影响

张欣睿; 于锋; 闫宏红; 谭国杰; 周毅波; 刘学奎

doi:10.13201/j.issn.1001-1781.2016.21.006

术前诱导化疗对晚期可手术切除的舌体鳞状细胞癌预后生存的长期影响

- 1 广州市耳鼻咽喉头颈外科医院广州市第十二人民医院耳鼻咽喉头颈外科(广州, 510060);
- 2 广州医科大学耳鼻咽喉头颈外科研究所;
- 3 中山大学肿瘤防治中心头颈科;
- 4 华南肿瘤学国家重点实验室

详细信息

通讯作者: 刘学奎,E-mail:liuxk@sysucc.org.cn

中图分类号: R739.6

收稿日期: 2016-09-20

The effect of preoperative induction chemotherapy on long-term survival of patients with advanced squamous cell carcinoma of the oral cavity tongue

- 1 Department of Otorhinolaryngology-Head and Neck Surgery, Guangzhou Ear Nose Throat Head and Neck Surgery Hospital, Guangzhou, 510060, China;
- 2 Institute of Otolaryngology Head and Neck Surgery of Guangzhou Medical University;
- 3 Department of Head and Neck Surgery, Cancer Center of Sun Yat-sen University;
- 4 State Key Laboratory of Oncology in South China

More Information

Corresponding author: LIU Xuekui, E-mail: liuxk@sysucc.org.cn

Received Date: 20 September 2016

摘要

摘要: 目的:探讨诱导化疗达到病理完全缓解(pCR)对可手术切除的Ⅲ/Ⅳ期舌体鳞状细胞癌患者生存和预后的长期影响。方法:选取1996-06-2005-12期间中山大学附属肿瘤医院首治、经病理检查确诊且随访资料完整、可手术切除的73例晚期舌鳞状细胞癌患者。所有患者均行三程PF(顺铂加5-FU)方案诱导化疗加手术和(或)放疗,回顾性分析其5年总生存率、局部控制率和治疗失败的可能原因。结果:全组随访时间为1.9~188.0个月,中位随访时间70.9个月,24例患者仍存活,其中23例患者生存时间大于10年。17例(23.3%)患者达到临床完全缓解(CR),44例(60.3%)临床部分缓解(PR),12例(16.4%)肿瘤稳定或进展,总有效率为83.6%。依据手术标本,14例(19.2%)达到pCR,59例(80.8%)病理PR。单因素分析示:肿瘤大小、有无区域淋巴结转移、临床分期、不同疗效反应和有无pCR是影响患者生存的独立因素(P＜0.05)。多因素分析示:颈部淋巴结转移、不同化疗疗效反应和有无pCR是影响患者预后生存的重要因素(P＜0.05)。所有患者5年总体生存率(OS) 为59.8%,22例 (30.1%)复发,局控率为69.9%。诱导化疗临床有效(CR+PR)患者5年OS为62.5%,明显高于无效患者(41.7%)。pCR患者5年OS为92.9%,未达到pCR患者5年OS为47.9%,2组之间的生存率差异有统计学意义(P＜0.05)。结论:对于可手术切除的晚期舌鳞状细胞癌,诱导化疗联合手术和(或)放疗等综合治疗方案是可行有效的治疗方法。虽然诱导化疗的缓解率有限,但有效缓解与患者较好的预后密切相关,尤其是达到pCR者。
- 舌肿瘤 /
- 鳞状细胞癌 /
- 诱导化疗
Abstract: Objective: To discuss the long-term efficency of preoperative induction chemotherapy(IC)± radiotherapy on patients with resectable stage Ⅲ or Ⅳ squamous cell carcinoma of the oral cavity tongue(SCCOT).Method: During June 1996 to December 2005, 73 patients with locally advanced SCCOT treated preoperatively with IC(3 cycle of cisplatin and 5-fluorouracil) followed by surgery(resection of the primary tumor and neck)± radiotherapy in the Cancer Center of Sun Yat-sen University were enrolled in our study. Five-year overall survival rates(OS), local control rate and reasons of treatment failure were analyzed retrospectively.Result: The follow-up time was 1.9 to 188.0 months, and the median follow-up time was 70.9 months.Among that,24 cases(32.9%) were still alive, of which 23 patients survival time is more than 10 years until the deadline of the follow-up. After IC, 17 patients(23.3%) had clinical complete response; 44 patients(60.3%) had a clinical partial response; 12 patients(16.4%) had no response or progression, and an overall response rate was 83.6%(65/73). On final surgical pathology, 14 patients(19.2%) had pathological complete response; 59 patients(80.8%) had histological incomplete response(residual tumor). Univariate analysis showed that the tumor size(P<0.05), cervical lymphatic metastasis(P<0.05),clinical stage(P<0.05),the different clinical remissions(P<0.05),had or not pathological complete remission(P<0.05) were risk factors affecting prognosis(P<0.05).Multivariate analysis indicated that cervical lymphatic metastasis cervical lymphatic metastasis(P<0.05), the different clinical remissions(P<0.05), had or not pathological complete remission(P<0.05) were independent factors for prognosis.Five-year OS of clinical effective of IC was 62.5%, apparently higher than the invalid effect 41.7% (P<0.05). Five-year OS of pCR was 92.9%,while have no pCR was 47.9%(P<0.05). A significant difference between the two groups was also found.During whole follow-up time, 22 patients developed recurrence. Five-year OS was 59.8%, local control rate were 69.9%.Conclusion: IC plus surgery with or without postoperative radiotherapy was a treatment modality that was tolerated with encouraging activity and survival outcome in patients with advanced resectable SCCOT. Response rate with this IC regimen was limited, but the responders were associated with excellent prognosis.
- oral tongue neoplasms /
- squamous cell carcinoma /
- induction chemotherapy

HTML全文

参考文献(17)

[1]	宋明,陈福进,郭朱明,等. 联合化疗在118例晚期头颈鳞状细胞癌中的作用[J].中山大学学报(医学科学版),2009,30(5):628-629.
[2]	PIGNON J P, LE MAITRE A, MAILLARD E, et al. Meta-analysis of chemotherapy in head and neck cancer(MACH-NC):an update on 93 randomised trials and 17,346 patients[J]. Radiother Oncol, 2009,92:4-14.
[3]	BOSSI P, LOVULLO S, GUZZO M, et al. Preoperative chemotherapy in advanced resectable OCSCC:long-term results of a randomized phase Ⅲ trial[J]. Ann Oncol, 2014,25:462-466.
[4]	GRAU J J, DOMINGO J, BLANCH J L, et al. Multidisciplinary approach in advanced cancer of the oral cavity:outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy[J]. Oncology, 2002,63:338-345.
[5]	LEON X, QUER M, ORUS C, et al. Histologically negative specimens after induction therapy:frequency and impact on survival[J]. Head Neck, 2000,22:808-813.
[6]	伍国号,魏茂文,宋陈曾,等.诱导化疗在中晚期舌癌治疗中的价值[J].癌症, 2002,21(1):3-5.
[7]	SCHWAM Z G, JUDSON B L. Improved prognosis for patients with oral cavity squamous cell carcinoma:Analysis of the National Cancer Database 1998-2006[J]. Oral Oncol,2016,52:45-51.
[8]	KIES M S, BOATRIGHT D H, LI G, et al. Phase Ⅱ trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults[J]. Head Neck,2012,34:1255-1262.
[9]	ZHONG L P, ZHANG C P, REN G X, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol,2013,31:744-751.
[10]	HITT R, LOPEZ-POUSA A, MARTINEZ-TRUFERO J, et al. Phase Ⅲ study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer[J]. J Clin Oncol, 2005,23:8636-8645.
[11]	KIRITA T, OHGI K, KAWAKAMI M, et al. Primary tumour resection of tongue carcinoma based on response to preoperative therapy[J]. Int J Oral Maxillofac Surg, 2002,31:267-272.
[12]	KIRITA T, SHIMOOKA H, YAMANAKA Y, et al. Prognostic value of response to preoperative chemoradiotherapy and residual tumor grades in tongue carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2001,91:293-300.
[13]	SHIBUYA Y, TANIMOTO H, UMEDA M, et al. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer[J]. Kobe J Med Sci, 2004,50:1-7.
[14]	OLASZ L, ORSI E, MARKO T, et al. Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer(OSCC)[J]. Cancer Metastasis Rev,2010,29:607-611.
[15]	何升腾,焦晓辉,刘欧胜,等.1170例舌癌的临床治疗方法分析[J]. 重庆医学, 2014,43(3):671-673.
[16]	WOOLGAR J A, ROGERS S, WEST C R, et al. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection[J]. Oral oncol, 1999,35:257-265.
[17]	CHUMMUN S, MCLEAN N R, RAGBIR M. Surgical education:neck dissection[J]. Br J Plastic Surg, 2004,57:610-623.